Payment overview · 2025
General Payments
$2,441.40
112 reported records · 20 companies
Healthcare provider profile · identity verified
Scott Mcwilliams, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · ROCKY POINT, NY · NPI 1013918812
Verified facts
What the public records show
CMS Open Payments records show Scott Mcwilliams, MD received $2,441.40 in general payments during 2025 across 112 reported records.
ABBVIE INC. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Gamunex-C, Hizentra, Nuplazid, Nurtec Odt, Qulipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Nuplazid by this doctor in 2024.
CSL Behring reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Hizentra as an associated drug or biological on 13634 records involving 4691 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Hizentra by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Gamunex-C by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $581.54 | 23.8% | 30 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $239.51 | 9.8% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $223.57 | 9.2% | 9 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $209.64 | 8.6% | 10 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $201.43 | 8.2% | 14 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $155.76 | 6.4% | 6 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$113.78 | 4.7% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $96.26 | 3.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $91.43 | 3.7% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $88.78 | 3.6% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$74.57 | 3.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $62.39 | 2.6% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $52.90 | 2.2% | 2 | 2025 |
| ITF Therapeutics LLC | Unresolved — no canonical attribution shown | $52.73 | 2.2% | 2 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $44.27 | 1.8% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $43.22 | 1.8% | 2 | 2025 |
| CSL Behring | Unresolved — no canonical attribution shown | $36.19 | 1.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $29.35 | 1.2% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $23.59 | 1.0% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $20.49 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,441.40 | 112 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $363.34 | 18 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $338.48 | 19 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $223.57 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $199.13 | 8 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $185.52 | 9 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $155.76 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $148.23 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $119.94 | 5 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $113.78 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $107.34 | 9 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $96.26 | 5 | 2025 |
Source payment records
|
|||||
| Fintepla Normalized: fintepla |
Drug | UCB, Inc. | $91.28 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART Normalized: vyvgart |
Drug | ARGENX US, INC. | $89.70 | 5 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $88.78 | 3 | 2025 |
Source payment records
|
|||||
| PERCEPT PC BRAINSENSE Normalized: percept pc brainsense |
Device | Medtronic, Inc. | $74.57 | 2 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $57.17 | 2 | 2025 |
Source payment records
|
|||||
| Gamunex-C Normalized: gamunex c |
Biological | Grifols USA, LLC | $52.90 | 2 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $44.27 | 2 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $43.22 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $42.27 | 2 | 2025 |
Source payment records
|
|||||
| Hizentra Normalized: hizentra |
Biological | CSL Behring | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.35 | 1 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $27.18 | 2 | 2025 |
Source payment records
|
|||||
| Gocovri Normalized: gocovri |
Drug | MDD US Operations, LLC | $23.59 | 1 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $20.49 | 1 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 41 | exact normalized | Medicare Part D |
| Gamunex-C gamunex c |
2025 | Gamunex-C | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Hizentra hizentra |
2025 | Hizentra | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 62 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 44 | exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
41 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| CSL Behring Exact reporting entity; no affiliate inference |
2025 | Hizentra open payments reported associated product |
CMS Open Payments — General Payments 13634 supporting records · 4691 recipient NPIs · example record 1232339012 |
Hizentra · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
62 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Galantamine Er | Galantamine Hbr | 453 | 128 |
| Memantine Hcl Er | Memantine Hcl | 250 | 69 |
| Ropinirole Er | Ropinirole Hcl | 116 | 29 |
| Gabapentin | Gabapentin | 112 | 29 |
| Levetiracetam | Levetiracetam | 96 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 28 |
| Primidone | Primidone | 85 | 23 |
| Quetiapine Fumarate | Quetiapine Fumarate | 85 | 18 |
| Donepezil Hcl | Donepezil Hcl | 82 | 23 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 71 | 21 |
| Alprazolam | Alprazolam | 68 | 27 |
| Celecoxib | Celecoxib | 68 | 21 |
| Pregabalin | Pregabalin | 66 | 13 |
| Topiramate | Topiramate | 66 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 62 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 52 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 51 | 18 |
| Rasagiline Mesylate | Rasagiline Mesylate | 51 | 14 |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 49 | 11 |
| Propranolol Hcl | Propranolol Hcl | 45 | 16 |
| Baclofen | Baclofen | 44 | 12 |
| Qulipta | Atogepant | 44 | 11 |
| Ubrelvy | Ubrogepant | 44 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 42 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 42 | 14 |
| Botox | Onabotulinumtoxina | 41 | 11 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Phenobarbital | Phenobarbital | 37 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 36 | 13 |
| Propranolol Hcl Er | Propranolol Hcl | 35 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 34 | 11 |
| Zonisamide | Zonisamide | 34 | suppressed |
| Lamotrigine | Lamotrigine | 32 | suppressed |
| Lacosamide | Lacosamide | 31 | suppressed |
| Memantine Hcl | Memantine Hcl | 29 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 28 | suppressed |
| Clonazepam | Clonazepam | 27 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Carbamazepine | Carbamazepine | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 25 | suppressed |
| Eletriptan Hbr | Eletriptan Hydrobromide | 23 | suppressed |
| Modafinil | Modafinil | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 20 | suppressed |
| Keppra | Levetiracetam | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 19 | 11 |
| Lorazepam | Lorazepam | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Dalfampridine Er | Dalfampridine | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 14 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Hizentra | Immun Glob G(Igg)/Pro/Iga 0-50 | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Meloxicam | Meloxicam | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,441.40 · 112 records | ABBVIE INC. | BOTOX, CREXONT, Fintepla, Gamunex-C, Gocovri, Hizentra, INBRIJA, KESIMPTA, KISUNLA, NUPLAZID, NURTEC ODT, OCTAGAM IMMUNE GLOBULIN (HUMAN), PANZYGA, PERCEPT PC BRAINSENSE, QULIPTA, REXULTI, Rystiggo, Symbravo, UBRELVY, ULTOMIRIS, VALTOCO, VRAYLAR, VUMERITY, VYALEV, VYEPTI, VYVGART, VYVGART HYTRULO, Xeomin, ZAVZPRET | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error